(Q77160540)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11705432%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

title

Active-control equivalence trials and antihypertensive agents (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11705432%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

author name string

F A McAlister

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11705432%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

D L Sackett

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11705432%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

publication date

1 November 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11705432%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Medicine

3 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11705432%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

volume

111

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11705432%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11705432%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

page(s)

553-558

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11705432%20AND%20SRC:MED&resulttype=core&format=json

Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect

3 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

Scientific and ethical issues in equivalence trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

Claims of equivalence in medical research: are they supported by the evidence?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

When placebo controlled trials are essential and equivalence trials are inadequate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

Are β-Blockers Efficacious as First-line Therapy for Hypertension in the Elderly?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

7 January 2021

Noninferiority trials

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

Trials to assess equivalence: the importance of rigorous methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

Significance Testing to Establish Equivalence between Treatments, with Special Reference to Data in the Form of 2 x 2 Tables

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

"Proving the null hypothesis" in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

Bias in analytic research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. United Kingdom prospective diabetes study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

Statistical power, sample size, and their reporting in randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900900-7

10.1016/S0002-9343(01)00900-7

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11705432%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

1 reference